Seeking Alpha

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III...

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III study of newly diagnosed multiple myeloma patients. Shares +2.5% premarket. (PR)
Comments (1)
  • Celgene will be at $150.00 near term.
    11 Jul 2013, 03:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)